Highlights
About
Necrosis Inhibition Technology
Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis. The companys drug-development process is based on a new platform for anti-necrosis technology. The prevention and treatment of necrosis is significant to the treatment of numerous pathological conditions and diseases. Ela Pharmas technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathways. Ela Pharmas first line of anti-necrosis agents is based on small molecules with structural features suitable for inhibiting a specific cellular target, which were found to significantly inhibit cell necrosis at particularly low concentrations.
Identity
| Name | Ela Pharma |
|---|---|
| Slug | ela-pharma |
| Type / kind | startup |
| Crunchbase ID | ela-pharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkIyPrK8IDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Dulchin St 16/6, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://www.elapharma.com/ |
|---|---|
| https://www.linkedin.com/company/18221536 |
Classifications
Funding
| Total raised | $77K |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}